The STEAL study is comparing two different 'fixed-dose combination' treatments. These are: abacavir combined with lamivudine - marketed in Australia as Kivexa -and tenofovir combined with emtricitabine - marketed as Truvada.
Both treatments are taken in combination with other antiretrovirals from different classes. The study will compare the pills for safety and for effectiveness against HIV.
The study is due for completion in August 2008.
This study compares darunavir/r to lopinavir/r (the 'r' signifies that a small dose of ritonavir is also used) in people who are treatment experienced.
The study will compare these two approaches for their safety and tolerability, as well as their effectiveness in fighting HIV.
This study is comparing darunavir boosted with low-dose ritonavir (TMC 114/r) with lopinavir boosted with low-dose ritonavir (Kaletra) in people who have never taken any antiretroviral treatment before. All people on the study will also be treated using the fixed-dose combination of tenofovir combined with emtricitabine (Truvada).
The two approaches will be compared for safety, tolerability and effectiveness in fighting HIV.
The aim of the study is to identify any changes in the HBV DNA that might be associated with resistance to tenofovir, to determine how long any changes take to occur and the effect of these changes on the clinical response to tenofovir.
This study looked at the new protease inhibitor (PI) darunavir and how safe, effective and easy-to-take it is with an 'optimised background regimen' including enfuvirtide (T-20).
The trial enrolled people who had been on triple-class therapy before but had never had enfuvirtide or darunavir.
This study is looking at how safe and effective tipranavir is (with low-dose ritonavir) compared to other protease inhibitor-based regimens in people who are highly treatment experienced.
This trial is looking at how safe, easy-to-take and effective a combination containing atazanavir/r is compared to one containing lopinavir/r.
The other antiretrovirals taken by both arms of the study are tenofovir and emtricitabine given in a fixed-dose combination pill marketed as Truvada.
We know that adherence is important for treatment success, so this study compares a once-a-day regimen with a twice-a-day one.
The purpose of the study is to compare the effectiveness of 3 different treatment regimens in reducing or clearing the Hepatitis B Virus in patients infected with HIV and Hepatitis B (co-infection)
This study was going to look at the benefits of adding T-20 to people's existing regimens, but recruitment was too slow so the study has been cancelled. Participants were to be randomized to receive T-20 in addition to their current antiretroviral therapy or to continue their current antiretroviral therapy alone.
This information was retrieved from the Treataware website (www.treataware.info) on 22 Nov 2008. For further information, please consult the website or call the NAPWA office on 02 8568 0300.